Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis

Clicks: 280
ID: 6473
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #935 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis Martha K Daddario1, Jennifer K Hagerman2, Michael E Klepser21Spectrum Health, Grand Rapids, Michigan; 2Ferris State University College of Pharmacy, Kalamazoo, Michigan, USAAbstract: Progressive obstructive lung disease is a characteristic component of cystic fibrosis (CF). It is the pulmonary manifestations, including obstruction and endobronchial infection, which directly contribute to the premature mortality of patients affected with CF. Due to the devastating effects on the pulmonary system, interest abounds in ways to improve antimicrobial delivery to the lungs and to impact clinical patient outcomes positively, whilst minimizing systemic toxicities. Recently, aztreonam lysine for inhalation solution, a new monobactam formulation, was approved by the US Food and Drug Administration for use in a subgroup of CF patients with Pseudomonas aeruginosa to improve respiratory symptoms. The purpose of this review is to present a summary of relevant pharmacologic, microbiologic, and clinical data related to the use of aztreonam lysine for inhalation in patients with CF.Keywords: aztreonam, cystic fibrosis, inhaled, aerosolized, antibiotic, Pseudomonas aeruginosa
Reference Key
martha2010clinicalinfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Martha K Daddario;Jennifer K Hagerman;Michael E Klepser and
Journal Infection and drug resistance
Year 2010
DOI
10.2147/IDR.S7838
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.